Tumor immunotherapy is only effective in a fraction of patients due to a low response rate
and severe side effects, and these challenges of immunotherapy in clinics can be addressed …

Radiotherapy is used in> 50% of patients with cancer, both for curative and palliative
purposes. Radiotherapy uses ionizing radiation to target and kill tumour tissue, but normal …

Decades of advancements in immuno-oncology have enabled the development of current
immunotherapies, which provide long-term treatment responses in certain metastatic cancer …

Immune checkpoint blockade (ICB) has revolutionised the treatment of solid tumours, yet
most patients do not derive a clinical benefit. Resistance to ICB is often contingent on the …

The combination of radiation and immunotherapy is currently an exciting avenue of pre-
clinical and clinical investigation. The synergy between these two treatment modalities has …

Radiotherapy (RT) is still one of the standard cancer therapies, with up to two third of all
cancer patients with solid tumors being irradiated in the course of their disease. The aim of …

Near-infrared photoimmunotherapy (NIR-PIT) induces immunogenic cell death but has
mostly failed to induce durable antitumor responses in syngenic tumor mouse models. We …

Background Radioresistance represents a major problem in the treatment of head and neck
cancer (HNC) patients. To improve response, understanding tumor microenvironmental …

Evidence to date shows that immune checkpoint inhibitors have little benefit in most patients
with head and neck squamous cell carcinoma (HNSCC). Intense interest is focused on …

Immunogenic cell death (ICD) is a stress-driven form of regulated cell death (RCD) in which
dying tumor cells' specific signaling pathways are activated to release damage-associated …